Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: results from a single center study

New antithrombotic therapies have significantly improved the outcomes of patients with Acute Coronary Syndromes (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits. However, ticagrelor treatment has been associated with a potential raise in serum uric acid (SUA), whose contribution to endothelial dysfunction and pro-thrombotic status may affect the risk of acute cardiovascular events in patients requiring dual antiplatelet therapy (DAPT). The aim of the present study was to compare the impact of the antiplatelet agents ticagrelor or clopidogrel on SUA levels and their effect on platelet reactivity.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research